

Prof Frank Behrens
Professor Frank Behrens is Professor of Translational Rheumatology, Immunology and Inflammation Medicine and Head of the Inflammation Clinic, University Hospital, Frankfurt am Main, Germany, and Deputy Director, Fraunhofer Institute for Translational Medicine & Pharmacology (ITMP), Goethe University, Frankfurt am Main. He is also a member of the board of directors of the Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD).
Professor Behrens studied biology at the Johannes Gutenberg University in Mainz, Germany, before going on to study human medicine. He completed his doctorate in haematology and oncology before training in internal medicine and rheumatology.
Professor Behrens' main research interest is the pathophysiological understanding of spondyloarthritis, rheumatoid arthritis and mixed connected tissue disease. The focus is on understanding the links between these rheumatic conditions and associated skin and bowel diseases. The aim of the work is to develop new drug therapies and implement personalised treatment approaches using combined biomarker analyses and new imaging techniques. Since 2001, he has gained experience in clinical research and development as Principal Investigator, Chief Investigator and Managing Investigator. He is responsible for several investigator-initiated studies in rheumatic diseases.
Professor Behrens has published numerous articles in peer-reviewed journals and is author of several textbooks in the field of rheumatic diseases.
Professor Behrens is a member of various international committees and study groups such as the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the Expert Panel Measures in Pulmonary Arterial Hypertension Related to Outcome of Systemic Sclerosis (EPOSS) and the Psoriatic Arthritis Genetic European Consortium (PAGE).

Evidence-based approach to medical management based on the European guidelines for HS
Latest evidence-based strategies for effective HS medical management including antibiotics and biologic therapy

Informed decisions for effective HS management
Different HS phenotypes and disease severity scores: their role in informing management decisions

The role of surgery in HS management: Optimising patient results
Surgical management of HS, through minor procedures to more complex interventions

Recognising HS symptoms: Diagnosis and what you need to know
Key criteria for diagnosing HS, common misdiagnoses and how AI can be used to assess disease severity

Taking a holistic approach: HS and its comorbidities
HS often presents with comorbidities extending beyond the skin. A holistic approach is essential for effective HS management

The invisible impact of HS: Hearing the patient experience
HS presents diverse challenges for patients, across many key aspects of life. Insights into these complex burdens provides the foundation for essential support